ArticleThe Journal of dermatology2026
Elevated Risk of Herpes Zoster in Vitiligo Patients: A Nationwide Population-Based Cohort Study of Taiwan.
Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Emerging therapies for vitiligo, such as Janus kinase (JAK) inhibitors, have raised concerns about an increased risk of herpes zoster (HZ), emphasizing the need to clarify the baseline HZ risk in patients with vitiligo. This study aimed to determine whether vitiligo itself is associated with a higher risk of HZ and to identify potential modifying factors, including systemic treatments. Using Taiwan's Longitudinal Health Insurance Database from 2010 to 2022, a retrospective nationwide cohort study was conducted. Patients with vitiligo were identified through diagnostic codes and matched in a 1:4 ratio with non-vitiligo controls by age, gender, index date, and comorbidities using propensity score matching. Subgroup analyses evaluated HZ risk among patients receiving systemic treatments, including phototherapy and immunosuppressants. A total of 79 910 individuals were included after matching. During the study period, the incidence of herpes zoster was significantly higher in patients with vitiligo than in controls (7.78% vs. 2.72%, p < 0.001). After adjusting for potential confounders, vitiligo remained independently associated with an increased risk of HZ (adjusted hazard ratio [aHR]: 1.532). The risk of HZ increased with age and was higher among female patients. Subgroup analysis further revealed that vitiligo patients receiving systemic therapy had the greatest susceptibility to HZ, especially those treated with cyclosporine (aHR: 1.891), methotrexate (aHR: 1.981), and systemic corticosteroids (aHR: 1.474). In conclusion, this large population-based study demonstrates that vitiligo is an independent risk factor for herpes zoster, and systemic immunosuppressive therapies further augment this risk. Clinicians should be aware of the potentially increased vulnerability to HZ among patients with vitiligo, particularly in older or female individuals. These findings may help inform general clinical considerations regarding preventive strategies, including herpes zoster vaccination, to reduce the risk of infection-related complications in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.